To provide a very important update to all the existing shareholders.  We have made significant progress over the last 2 quarters, some highlights will be:

  *   Executing a license agreement to utilize 20 years of data, with FDA authorization to utilize the data.  A multi-year, multi-billion dollar shortcut

  *   Final Clinical Study Report from the Phase 1 Trial Received and Accepted by FDA

  *   Additional FDA Progress

  *   Discussions with several strategic pharma companies

  *   Launch of the Series B Raise